Neovasc Inc. NVCN

Are Boston Scientific's Lotus Valve Woes Neovasc's Gain?

[Stonehouse97]

This scenario puts Neovasc's Tiara in an interesting position with Boston Scientific's 15% equity stake in Neovasc...IMHO

"Last February, the company voluntarily recalled all its core Lotus Valve devices, including Lotus with Depth Guard. This dragged down its shares by 9.4% in the pre-market trading session (per an article on Medical Device and Diagnostic Industry).

Sadly, again in November, Boston Scientific announced a further delay in the re-launch of the LOTUS Edge Aortic Valve System after it failed to meet the committed timeline, hurting shareholder sentiments even more. Per an article on the Medical Device and Diagnostic Industry, the company had opted out from the Piper Jaffray healthcare conference in New York on the same day, pulling down the stock by 7.5%, which was followed by a decline in its market cap by around $2.9 billion.

Meanwhile, rejoicing at this situation is Edwards Lifesciences Corporation EW, a leading player in the TAVR market. Encouragingly, the company’s shares have soared 45.4% since Lotus Valve devices’ recall last February."

 

Boston Scientific Lotus Valve Issues - Neovasc's Gain?

[Barewood]

All I can say is Neovasc is being headed up by a more trusted experienced management and has regulatory approval both in the U.S. and Europe. At year end it has 17.5 Mil in the bank; 48 patients with Tiera implants; and the experts assigned this stock to gain by 2975% over this year with a price tag high of $5.00. I do believe we are seeing our bottom right now and is poised to rebound.